Ionis Pharmaceuticals Shares Rise 6% in 4 Days Since Partnership
Ionis Pharmaceuticals (IONS) and partner Roche reported a 43.1% reduction in proteinuria for sefaxersen in a Phase 3 study treating IgA nephropathy populations.
ALFA USA News
Straight from the SEC filing
Every SEC filing by IONIS PHARMACEUTICALS INC that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (23 Oct 2026). Not a valuation or a recommendation.
Down 36.9% over the last month ($44.38 on 19 Oct → $28.01 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $44.38 |
|---|---|
| 20 Oct | $45.40 |
| 21 Oct | $44.27 |
| 22 Oct | $43.91 |
| 23 Oct | $42.93 |
| 26 Oct | $43.42 |
| 27 Oct | $43.96 |
| 28 Oct | $44.90 |
| 29 Oct | $44.39 |
| 30 Oct | $43.52 |
| 2 Nov | $41.24 |
| 3 Nov | $40.42 |
| 4 Nov | $40.15 |
| 5 Nov | $38.80 |
| 6 Nov | $39.42 |
| 9 Nov | $31.00 |
| 10 Nov | $28.19 |
| 11 Nov | $28.33 |
| 12 Nov | $27.31 |
| 13 Nov | $29.06 |
| 16 Nov | $28.01 |
Ionis Pharmaceuticals (IONS) and partner Roche reported a 43.1% reduction in proteinuria for sefaxersen in a Phase 3 study treating IgA nephropathy populations.
Ionis Pharmaceuticals and partner GSK receive FDA approval for HIBSAGO (bepirovirsen), achieving a 19% functional cure rate for chronic hepatitis B patients.
Track IONIS PHARMACEUTICALS INC live
Get the next IONIS PHARMACEUTICALS INC SEC filing seconds after it lands.